Research
Lumbrokinase
7 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: results from a multicenter, randomized, parallel-group and controlled clinical trial.
This multicenter, randomized controlled trial assessed the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention in 310 patients. The treatment group showed favorable outcomes in fibrinogen levels, carotid IMT, plaque detection, NIHSS scores, and incidence of vascular and cerebral vascular events compared to the control group.
[Effect of lumbrokinase on patients with acute and moderate risk pulmonary thromboembolism].
Retrospective analysis of 60 patients with acute and moderate risk pulmonary thromboembolism treated with lumbrokinase combined with low molecular heparin and sequential warfarin. The lumbrokinase group showed significant improvements in several clinical parameters compared to the control group, indicating better clinical efficacy and safety.
Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
RCT investigating the effect of lumbrokinase on anticoagulation and fibrinolysis in cerebral infarction patients. The treatment group showed significant improvements in stroke score, prolonged KPTT, increased t-PA activity and D-dimer levels, and decreased fibrinogen content, suggesting lumbrokinase benefits cerebral infarction treatment by inhibiting intrinsic coagulation and activating fibrinolysis.
The Safety and Tolerability of Lumbrokinase DLBS1033 in Healthy Adult Subjects.
This was a 2-arm, randomized, double-blind, placebo-controlled, cross-over study evaluating the safety and tolerability of Lumbrokinase DLBS1033 in healthy adults. The study found no significant differences in hemostasis, hematological parameters, blood chemistry, or ECG interpretation between DLBS1033 and placebo, indicating that DLBS1033 was safe and tolerable.
Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: a pilot study.
A single-armed cohort study evaluated the efficacy of oral lumbrokinase in 10 patients with stable angina. After 30 days of treatment, myocardial perfusion improved as indicated by a decrease in Summed Stress Score and Summed Difference Score by 39% and 37%, respectively. Anginal symptoms improved in 6 out of 10 patients, with no adverse reactions observed.
Novel thrombolytic therapy discovered from traditional oriental medicine using the earthworm.
The study extracted a fibrinolytic enzyme from the earthworm Lumbricus rubellus and tested its effects on fibrinolytic activity in 7 healthy volunteers. The enzyme showed potential as an oral thrombolytic agent, with increased fibrinolytic activities and changes in t-PA antigen levels over 17 days.
Safety of CA-7 (fibrinolytic enzyme) for direct pulmonary artery perfusion.
The paper investigates the safety of CA-7, a fibrinolytic enzyme, for direct pulmonary artery perfusion. No abstract is available to provide further details.